571 - Safety and Immunogenicity of Coadministered Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine With and Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age

Saturday, October 19, 2024

1:45 PM – 2:03 PM US PT

Location: 408 A

Co-Author(s)

Disclosure(s):

Joel Neutel, MD: Pfizer Inc: Employee

Rahsan Erdem, MD: Pfizer Inc: Employee, Stocks/Bonds (Private Company)

Qin Jiang, PhD: Pfizer: Salary, Stocks/Bonds (Public Company)

Kevin Cannon, MD: No financial relationships to disclose

Helen Stacey, M.D., MPH: No financial relationships to disclose

Ryan Newton, BSC/MBA: Pfizer Inc: Employee, Stocks/Bonds (Private Company)

Emily A. Gomme, Ph.D.: Pfizer Inc: Employee, Stocks/Bonds (Private Company)

Federico Mensa, MD: BioNTech: Employee, Stocks/Bonds (Public Company)

Ozlem Tureci, MD: BioNTech: Employee, Stocks/Bonds (Public Company)

Ugur Sahin, MD: BioNTech: Employee, Stocks/Bonds (Public Company)

Kena A. Swanson, Ph.D.: Pfizer: Employee of Pfizer, Stocks/Bonds (Public Company)

Iona Munjal, MD: Pfizer: Salaried employee, Stocks/Bonds (Public Company)

David Cooper, PhD: Pfizer, Inc.: Employee, Stocks/Bonds (Public Company)

Kenneth Koury, PhD: Pfizer Inc: Employee, Stocks/Bonds (Public Company)

Annaliesa S. Anderson, PhD: Pfizer, Inc.: Employee, Stocks/Bonds (Public Company)

Alejandra C. Gurtman, M.D.: Pfizer, Inc.: Employee, Stocks/Bonds (Public Company)

Nicholas Kitchin, MD: Pfizer Inc: Employee, Stocks/Bonds (Public Company)